edicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (A61K47)

Polymeric protein microparticles // 2642664
FIELD: pharmacology.SUBSTANCE: microparticles containing a core of therapeutic protein and a top layer of biocompatible and biodegradable polymer, and methods for production and application of these microparticles are proposed. The prolonged release of the therapeutic protein from the microparticles into saline is demonstrated over an extended period of time.EFFECT: group of inventions allows to expand the arsenal of available pharmaceuticals.18 cl, 3 dwg, 7 tbl, 9 ex
Pharmaceutical composition // 2642624
FIELD: pharmacology.SUBSTANCE: version 1 of the composition contains maleate indacaterol in an amount of 20-1200 μg in combination with fluticasone furoate in an amount of 0.5-800 μg or ciclesonide in an amount of 20-800 μg, lactose and optionally one or more pharmaceutically acceptable excipients. Version 2 of the composition contains maleate indacaterol in an amount of 20-1200 μg in combination with fluticasone furoate in an amount of 0.5-800 μg and tiotropium in an amount of 2.25-30 μg, lactose and optionally one or more pharmaceutically acceptable excipients. The composition is in a form suitable for administration once a day.EFFECT: composition according to the invention simplifies the mode of drug administration in the treatment of respiratory, inflammatory or obstructive airway diseases.2 cl, 49 ex
Complexes based on chondroitin for cutaneous absorption // 2642612
FIELD: pharmacology.SUBSTANCE: invention is a transdermal delivery composition comprising non-covalent complexes between non-sulphated chondroitin having a molecular weight of 5 to 100 kDa determined by exclusion chromatography and active ingredients selected from diclofenac or its salts and ketorolac or its salts.EFFECT: invention provides passage through the stratum corneum of the skin, penetration into the epidermis, through the mucous membrane, as well as delayed release of the active components.4 cl, 11 tbl, 7 ex
ethod for conserving and stabilizing proteins // 2642277
FIELD: biotechnology.SUBSTANCE: invention can be used for commercial development of the compositions used in the sanitary, pharmaceutical and cosmetic products, in particular cell growth factors such as epidermal growth factor (EGF) and fibroblast growth factor (bFGF). In accordance with the present invention, the proteins are placed in an anhydrous medium formed by oil components having hydrophilic properties and interacting with proteins while conserving their native conformation.EFFECT: increasing the stability of protein dispersion.1 cl

Composition for hyperlipidemia treatment containing oxyntomodulin derivative // 2642267
FIELD: biotechnology.SUBSTANCE: oxyntomodulin derivative with SEQ ID NO: 24, 25 or 26 fused to the Fc region of the immunoglobulin via a non-peptidyl polymer that covalently binds the oxyntomodulin derivative and the immunoglobulin Fc region is obtained.EFFECT: invention allows to obtain a conjugate of a oxyntomodulin derivative with a high ability to activate the GLP-1 receptor and a glucagon receptor compared to natural oxyntomodulin and to effectively lower the levels of total cholesterol, low density cholesterol and triglycerides in blood that have been elevated due to a high fat diet and to raise high-density cholesterol levels and high-density cholesterol - low-density cholesterol ratios.13 cl, 10 dwg, 3 tbl, 6 ex

Oral pharmaceutical compositions of testosterone esters and method for testosterone shortage treatment with their use // 2642244
FIELD: pharmacology.SUBSTANCE: invention concerns an oral pharmaceutical composition for testosterone shortage treatment for men, containing testosterone undecanoate dissolved in a medium containing at least one lipophilic surfactant and at least one hydrophilic surfactant with a ratio of the total number of lipophilic surfactants to the total number of hydrophilic surfactants (in/out), being in an approximate range from 6:1 to 3.5:1, while the dissolved testosterone undecanoate ranges from 18 to 22 wt % of the composition. The invention also relates to composition application for production of a drug for treatment of testosterone shortage or its symptoms in men and a treatment method, which includes oral intake of an effective amount of the pharmaceutical composition.EFFECT: application of the invention provides an opportunity to achieve a higher bioavailability, providing an effective therapeutic product based on testosterone for oral introduction, which can increase the levels of testosterone in the blood serum to clinically effective values, efficient oral testosterone therapy.23 cl, 10 tbl, 5 ex, 5 dwg

ethod of producing l-arginine nanocapsules // 2642233
FIELD: nanotechnologies.SUBSTANCE: invention relates to nanotechnology, namely to the method of producing L-arginine nanocapsules in sodium carboxymethyl cellulose. Method is characterized in that L-arginine is slowly added to the suspension of sodium carboxymethyl cellulose in methanol in the presence of 1 % of E472c preparation as a surfactant with stirring at 1,000 rpm, then 10 ml of petroleum ether is added, obtained suspension is filtered and dried at room temperature, the core/shell weight ratio being 1:1 or 1:3, or 5:1. Method ensures the simplification and acceleration of the process of producing nanocapsules, reduction in losses in the production of nanocapsules, and can be used in the food industry.EFFECT: method ensures the simplification and acceleration of the process of producing nanocapsules, reduction in losses in the production of nanocapsules, and can be used in the food industry.1 cl, 2 dwg, 4 ex

ethod of producing aecol nanocapsules // 2642232
FIELD: nanotechnologies.SUBSTANCE: invention relates to nanotechnology, particularly to method of producing AECOL nanocapsules in a xanthan envelope. Method is characterized in that AECOL is added to a suspension of xanthan gum in benzene in the presence of 0.01 g of E472c as a surfactant,then it is mixed at 1300 rpm, after 10 ml of carbon tetrachloride are added, after which obtained suspension is filtered and dried at room temperature, ratio of nucleus/shell is 1:1, or 1:3 or 3:1 or 1:5.EFFECT: method ensures the simplification and acceleration of the process of producing nanocapsules, reduction in losses in the production of nanocapsules, and can be used in the pharmaceutical and food industries.1 cl, 1 dwg, 5 ex
ethod of producing nanocapsules of dihydroquercetin in carrageenan // 2642230
FIELD: nanotechnologies.SUBSTANCE: invention relates to nanotechnology. Method for preparing nanocapsules of quercetin or dihydroquercetin in a coat of carrageenan is described. According to this method, quercetin or dihydroquercetin is added to a suspension of carrageenan in benzene in presence of 0.01 g of E472c as surfactant with stirring at 1000 rpm. Then, petroleum ether is added. Obtained suspension of nanocapsules is filtered off and dried at room temperature. Mass ratio of the core: the shell is 1:3 or 1:1.EFFECT: method provides simple and fast process of producing nanocapsules and increases mass output.1 cl, 2 dwg, 4 ex
ethod of producing nanocapsules of herbs having cardioactive action in pectin // 2642056
FIELD: pharmaceuticals.SUBSTANCE: invention refers to pharmaceutics, it relates to the method for producing nanocapsules of medicinal plants with cardiotonic effect, characterized by, that as a nanocapsule shell, high or low-esterified pectin is used, and as a core, hawthorn tincture, and the hawthorn tincture is added to a suspension of high- or low-esterified apple or citrus pectin in hexane in the presence of 0.01 g of E472c preparation as a surfactant while mixing at 1300 rpm, obtained suspension is filtered and dried at room temperature, weight ratio nucleus/shell is 1:3.EFFECT: invention allows to simplify and accelerate the process of producing nanocapsules and increase the output by mass.1 cl, 4 ex

ethod of producing medicinal plants nanocapsules with cardiotonic effect // 2642054
FIELD: nanotechnologies.SUBSTANCE: invention relates to the field of nanotechnology, in particular to a process for producing nanocapsules, and describes a method of producing medicinal plants nanocapsules with cardiotonic effect, which is characterized by the fact that hawthorn tincture is added to a suspension of xanthan gum in toluene, in the presence of 0.01 g of E472c preparation as a surfactant while mixing at 1300 rpm, the obtained suspension is filtered and dried at room temperature.EFFECT: method ensures the simplification and acceleration of the process of producing nanocapsules, reduction in losses in the production of nanocapsules, and can be used in the pharmaceutical and food industries.1 cl, 1 dwg, 4 ex
Cyclosporine suspensions a of form 2 // 2641963
FIELD: pharmacology.SUBSTANCE: group of inventions represents: an ophthalmic suspension, containing cyclosporine A of form 2 and some medium, where cyclosporine A of form 2 is characterized by peaks in X-ray diffractometer scanning with the radiation of Cu Kα, 2θ: 7.5, 8.8, 10.2, 11.3, 12.7, 13.8, 14.5, 15.6 and 17.5; method of preparation of cyclosporine composition, which includes the stages of mixing cyclosporine A of form 2 with the medium for producing the suspension; suspension quassation; ophthalmic suspension, containing particles of cyclosporine A of form 2; and the medium, in which the average particle size (d90) is less than about 10 micron; method of treatment of a condition selected from: dry eye syndrome, blepharitis, tarsal glands disease, impaired awareness of corneal, allergic conjunctivitis, atopic keratoconjunctivitis, spring keratoconjunctivitis and pterygium, including the stage of applying said ophthalmic suspension to the patient, being in this condition.EFFECT: increased bioavailability, reduced foreign body sensation and achieved high stability.15 cl, 18 dwg, 2 ex, 2 tbl
Gel including nifedipine and lidocaine hydrochloride (versions), application of gel including nifedipine and idocaine hydrochloride (versions), method for preparation of gel including nifedipine and idocaine hydrochloride, using nanotechnology // 2641570
FIELD: pharmacology.SUBSTANCE: method for gel preparation consists in preparation of two separate solutions and a nifedipine suspension, followed by mixing of the solutions and suspension at a temperature of 20-37°C for 1-9 hours with further filtration and gel preparation by addition of a gelling agent.EFFECT: invention implementation allows to obtain a gel with a high stability of gel properties, transparency, stability of properties for up to 2 years, the use of which allows to reduce the clinical symptoms of hemorrhoids up to their complete elimination, anal fissure healing and relief of pain after hemorrhoidectomy.3 cl, 1 tbl
ethod of producing triglycerides of medium-chain fatty acids // 2641307
FIELD: chemistry.SUBSTANCE: invention relates to the method of producing glycerol ethers (triglycerides) of medium-chain monocarboxylic fatty acids, which consists of the reaction of a free fatty acid precursor and glycerin in the presence of a catalyst under partial vacuum. The method of producing triglycerides of medium-chain fatty acid comprises the steps of: a) mixing glycerol with three molar equivalents or an excess of the said medium-chain fatty acids, each of the medium-chain fatty acids containing a chain of 6-12 carbon atoms; b) reacting the mixture of step (a) with a divalent or trivalent metal catalyst; and c) heating at a temperature of about 160 to about 180°C, under partial vacuum from 1 to 20 mm Hg, for a period of time sufficient to produce triglyceride.EFFECT: method provides the possibility of producing final triglycerides in high yield and high purity, the method provides the possibility of forming triglycerides without a solvent.23 cl, 5 ex, 1 tbl

Glp-1 peptides compositions and their production // 2641198
FIELD: pharmacology.SUBSTANCE: group of inventions concerns pharmaceutical compositions for treatment of diabetes or obesity, containing the first type of granules and the second type of granules, where the specified first type of granules contains the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and does not contain GLP-1 peptide, and where the specified second type of granules contains GLP-1 peptide and does not contain the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and also refers to methods for composition production and application in medicine.EFFECT: improving the bioavailability of the GLP-1 peptide.33 cl, 10 ex, 12 tbl
ethod for producing nanocapsules of dry extract of topinambur // 2641190
FIELD: nanotechnology.SUBSTANCE: method for obtaining nanocapsules of a dry extract of Jerusalem artichoke in a shell of pectin is described. As a nanocapsule, a low-esterified and highly esterified apple and citrus pectin is used, as a core - a dry extract of Jerusalem artichoke. Nanocapsules are prepared by mixing a mixture of pectin in toluene with 0.01 g of E472c as a surfactant, then adding a dry extract of Jerusalem artichoke into the mixture, precipitating with diethyl ether, followed by filtering out the resulting suspension and drying the nanocapsules. Mass ratio in nanocapsules core: shell is 1:3 or 5:1. The process of obtaining nanocapsules is carried out at 25°C for 15 minutes.EFFECT: simplification and acceleration of the nanocapsules production process and increase in yield by weight.4 dwg, 9 ex

ethod of betulin nanocapsules production // 2641188
FIELD: nanotechnology.SUBSTANCE: method for preparing betulin nanocapsules in a shell of xanthan gum is described. In the process, the betulin powder is added to a suspension of xanthan gum in isopropanol in the presence of 0.01 g E472c as a surfactant with stirring at 1300 rpm. Then butyl chloride is added. The resulting suspension is filtered and dried at the room temperature. The core shell ratio is 1:1 or 1:3.EFFECT: simplification and acceleration of the nanocapsules production process and increase in yield by weight.1 dwg, 3 ex
Agent for pyoinflammatory processes in soft tissues and mucous membranes // 2641095
FIELD: pharmacology.SUBSTANCE: invention is an agent for treatment of pyoinflammatory processes in soft tissues and mucous membranes in the form of a film that contains benzalkonium chloride, metronidazole, lidocaine hydrochloride, dimethyl sulfoxide, glycerol, sodium salt of carboxymethylcellulose and 5% solution of aminocaproic acid, with components in the agent being in a specific ratio of mass fractions.EFFECT: creation of an effective agent in the form of a film possessing antimicrobial, sorption, analgesic, wound healing and haemostatic action.4 tbl

Oral film-forming basis and preparation // 2641092
FIELD: pharmacology.SUBSTANCE: oral film-forming basis consists of food polymer soluble in water and in organic solvent, with a solubility parameter equal to 9.7-20 (cal/cm3)1/2, a foam-forming means selected from sodium or ammonium hydrocarbons, or sodium, magnesium, ammonium, potassium or calcium carbonate, and an auxiliary foam-forming means foaming in the presence of water and selected from L-ascorbic acid, potassium L-bitartrate, calcium dihydropyrophosphate, disodium dihydropyrophosphate, galacturonic acid, glucuronic acid, monosodium fumarate, aluminium-potassium sulphate, sodium DL-malate, sodium dihydrophosphate, dipotassium hydrophosphate, sodium dihydrophosphate and disodium hydrophosphate, wherein both foam-forming and auxiliary foam-forming means are not soluble in the specified organic solvent and included in the form of particles with an average size of 0.1 to 60 microns, as well as to the drug, including the medicinal product in the specified basis and to methods for their production.EFFECT: group of inventions provides a rapid oral dissolution profile and sufficient film strength, reduced stickiness, improved absorption.17 cl, 47 ex, 13 tbl, 1 dwg
Application of fullerene c60 aqueous solution as therapeutic agent at atopic dermatitis disease // 2641091
FIELD: pharmacology.SUBSTANCE: invention is application of a therapeutic agent for parenteral administration in atopic dermatitis, which is a water-salt solution consisting of fullerene C60, pluronic F-127 and physiological saline, where the components in the agent are in a certain ratio per ml of solution.EFFECT: reduction of allergic inflammation, skin regeneration improvement.1 tbl, 5 dwg
Composition for atopic dermatitis therapy based on fulleren // 2641041
FIELD: medicine.SUBSTANCE: composition includes an aqueous solution of fullerene C60, vaseline, sucrose palmitate, as well as parabens - nipasol and nipagin in a weight ratio of 4:3.78:2.2:0.001:0.001. The final content of fullerene in the composition is 0.005 to 0.012 wt %.EFFECT: invention allows reduction of inflammatory leukocyte infiltration of the epidermis.1 cl
ethod for polyelectrolite microcapsules preparation // 2641034
FIELD: biotechnology.SUBSTANCE: solutions of polycation-carrageenan with a concentration of 8.0-12.0 mg/ml in a buffer solution with pH of 4.7-4.8, peptides with a concentration of 3.5-4.5 mg/ml and polyanion chitosan with a concentration of 8.0-12.0 mg/ml in a buffer solution with pH of 4.7-4.8 are prepared and mixed originally in the ratio of 1:5:1, followed by consecutive addition of polyelectrolyte solutions in the ratio of 1:1 to achieve a lasting polyelectrolyte complex, which is stirred for 30 minutes, centrifuged at 400-500 rpm for 10-15 minutes, followed by supernatant removal, sediment is washed with 0.5 M sodium chloride solution and the microcapsules obtained are stored in the form of suspension or freeze-dried at plus 2-4°C.EFFECT: preparation of polyelectrolyte microcapsules that allow to deliver peptides from the embryonic tissues of birds to the intestines, bypassing the gastric environment, while maintaining their biological activity.3 ex

Filaments containing active components, suitable for oral supplementation, non-woven fabrics and methods of manufacturing them // 2640933
FIELD: medicine.SUBSTANCE: nonwoven fabric suitable for swallowing, used to deliver one or more active components, is described. Filaments containing filament-forming material and an additive suitable for supplementation of an active component are described. Non-woven fabrics and methods for manufacturing such filaments are described. The nonwoven fabric contains filaments that contain typically incompatible active components.EFFECT: improved connections.29 cl, 6 dwg, 5 ex

Rectal suppositories for prostate treatment containing lysyl-glutamyl-aspartyl-proline tetrapeptide // 2640931
FIELD: pharmacology.SUBSTANCE: invention describes rectal suppositories for treatment of prostate diseases, particularly chronic prostatitis, including chronic abacterial prostatitis (HAP), prostatic hyperplasia, benign prostatic hyperplasia, and for treatment of pre-and postoperative prostate conditions. Suppositories contain lysyl-glutamyl-aspartyl-proline tetrapeptide (0.0003-0.0010 grams), dimethylsulfoxide (0.014-0.05 g) and a base for suppositories in an amount sufficient to produce a suppository weighing 1.0 g.EFFECT: suppositories are stable during storage and highly effective for treatment of prostate diseases.5 cl, 1 dwg, 3 tbl, 6 ex

Cations of monovalent metals of dry powders for inhalations // 2640921
FIELD: pharmacology.SUBSTANCE: dry powders for treatment of respiratory diseases, consisting of inhaled dry particles, including salts of monovalent metals in quantities of at least 3% of the weight of dry particles and a pharmaceutically active substance, which represents an antibiotic, LABA, LAMA, a corticosteroid or a combination thereof. At that, dry particles in the dry powders are characterized by a volume geometric mean diameter of 5 mcm or less, tundish density between 0.45 g/cm3 and 1.2 g/cm3 and ratio of the volumetric mean geometric diameter measured at a dispersion pressure of 1 bar divided by the volumetric mean geometric diameter measured at a dispersion pressure of 4 bar is less than 1.5. Also, dry powders application for the manufacture of drugs for treatment and prevention of respiratory diseases and their exacerbations are disclosed.EFFECT: due to high dispersibility of dry particles, the group of inventions allows treatment and prevention of respiratory diseases through dry powders inhalation into the lungs of the patient, using only the energy of inhalation, without application of carrier particles or active inhalers.22 cl, 20 dwg, 28 tbl, 17 ex

Biodegradable devices based on silicon for therapeutic agents delivery // 2640918
FIELD: medicine.SUBSTANCE: biodegradable devices are described, such as implants for the controlled delivery of therapeutic agents, in particular large molecules such as proteins and antibodies. The devices contain a porous silicon carrier material impregnated with a therapeutic agent. An improved dosage form for controlled release of therapeutic agents can be used in vitro or in vivo to deliver the therapeutic agent during an estimated period of time, for example, several days, weeks or months.EFFECT: device can be used to treat or prevent the patient's conditions, such as chronic diseases.19 cl, 3 dwg, 6 tbl, 6 ex

Gastroretentive dosage form and delivery systems and method of their production using functionalized calcium carbonate // 2640914
FIELD: pharmacology.SUBSTANCE: group of inventions refers to instantly floating gastroretentive finished dosage form, represented as a tablet, mini-tablet, granules, cap or pellets and containing a pharmaceutically active ingredient, formulating aid and functionalized natural and/or synthetic calcium carbonate, which has Brunauer-Emmett-Teller surface area of 5-200 m2/g and is a product of reaction of the natural or synthetic calcium carbonate with pharmaceutically acceptable acid and carbon dioxide, formed by acid treatment and/or supplied from an external source, where the source of the natural calcium carbonate is isolated from marble, calcite, chalk, limestone, dolomite and/or their mixtures. The synthetic calcium carbonate is precipitated calcium carbonate, containing an aragonitic, vaterite or calcitic mineralogic crystal forms. It also relates to the method of its production and application of the functionalized natural and/or synthetic calcium carbonate for its production.EFFECT: instantly floating properties of said finished dosage form and long stay in the stomach.31 cl, 4 dwg, 3 tbl, 1 ex
ethod for obtaining of composition based on hyaluronic acid // 2640911
FIELD: cosmetology.SUBSTANCE: invention is a process for preparation of a composition for use as a dermatological excipient in cosmetic and medical applications in the form of a gel comprising a crosslinked first polymer, optionally a second polymer that can be crosslinked or uncross linked, and water, wherein the first and second polymers are selected from polysaccharide, and the process comprises at least steps (i), (ii) and (iv), and optionally step (iii), wherein step (i) is to crosslink a mixture including the first polymer and water, step (ii) is to finish the crosslinking of step (i), step (iii) is to optionally blend the product obtained in step (ii) with the second polymer, step (iv) consists in dialysis of the product obtained in step (ii) or in step (iii), wherein the dialysis step (iv) comprises steps (iv.1)-(iv.3)(iv.1) which is extrusion of the product, obtained in step (ii) or (iii) through the first sieve and then extrusion of the product extruded through the first sieve through the second sieve, in which the second sieve hole size is smaller than the first sieve hole size; or extrusion of the product, obtained in step (ii) or (iii) through the first sieve and then extrusion of the product extruded through the first sieve through the second sieve, and then extrusion of the product extruded through the second sieve through the third sieve, in which the second sieve hole size is smaller than the first sieve hole size, and the third sieve hole size is smaller than the second sieve hole size, where step (iv.2) is to fill the dialysis membrane with the product obtained in step (iv.1), step (iv.3) is to process the filled membrane obtained in step (iv.2) with dialysis solution.EFFECT: obtaining of exclusively homogeneous compositions.14 cl, 14 ex
Systems and compositions for postprocedure skin care and methods of application thereof // 2640504
FIELD: pharmacology.SUBSTANCE: invention is a topically-applied wound healing composition consisting of the following components: aluminium sulfate tetradecahydrate present in an amount from about 40.0 wt % to about 55.0 wt % on the basis of the weight of the topically-applied wound healing composition, calcium acetate monohydrate present in an amount from about 28.0 wt % to about 39.0 wt % on the basis of the weight of the topically-applied wound healing composition, common oat grain protein present in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, soy protein in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, whey protein present in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, chitosan present in an amount from about 0.25 wt % to about 50 wt % on the basis of the weight of the topically-applied wound healing composition, potassium sorbate present in an amount from about 0.25 wt % to about 10 wt % on the basis of the weight of the topically-applied wound healing composition and dextrin present in an amount from about 5 wt % to about 50 wt % on the basis of the weight of the topically-applied wound healing composition.EFFECT: effective healing of postprocedure wounds on the skin, high stability.23 cl, 4 dwg, 8 tbl, 4 ex

ethod of betulin nanocapsules production // 2640499
FIELD: nanotechnology.SUBSTANCE: method for producing betulin nanocapsules is characterized in that an apple or citrus pectin is used as the nanocapsule shell, and betulin is used as the nucleus. According to the method betulin powder is added to a suspension of high- or low-etherified pectin in methanol in the presence of 0.01 g of E472c drug as a surfactant at a stirring speed of 1000 rpm, then hexane is poured in. The resulting suspension pf nanocapsules is filtered and dried at room temperature. The core: shell ratio is 1:1 or 1:3.EFFECT: according to the invention the method provides simplification and acceleration of the nanocapsules production process and increase in the yield by weight.2 dwg, 6 ex

ethod for producing nanocapules of dry extract of topinambour in gellan gum // 2640490
FIELD: nanotechnology.SUBSTANCE: dry topinambour extract is added to a gellan gum suspension in methanol containing 0.01 g of E472c drug as a surfactant, stirred at 1000 rpm, then methylethylketone is added. The resulting nanocapsule suspension is filtered, washed with methylethylketone and dried, while the weight ratio of gellan gum to the dry topinambour extract is 1:1, 3:1, 5:1 or 1:5.EFFECT: method ensures simplification and acceleration of the nanocapsules production process, reduction of losses during the nanocapsules production and can be used in the pharmaceutical and food industries.4 dwg, 5 ex

ethod of production of nanocapsules of dorogov antiseptic excitor (dse) fraction 2 // 2640489
FIELD: nanotechnology.SUBSTANCE: method for production of Dorogov antiseptic excitor (DAE) nanocapsules fraction 2 in a shell of gellan gum is described. In the method DAE fraction 2 is added to a suspension of gellan gum in ethanol in the presence of 0.01 g of E472c drug as a surfactant at a stirring speed of 1300 rpm. Then hexane is added, the resulting precipitate is filtered and dried at room temperature. The core: shell ratio is 1:1, or 1:3, or 3:1.EFFECT: simplification and acceleration of the nanocapsules production process and increase in yield by weight.3 dwg, 4 ex

ethod for production of nanocapules of auxins // 2640488
FIELD: nanotechnology.SUBSTANCE: auxine is added to an agar agar suspension in isopropanol in the presence of a surface-active agent at a stirring speed of 1300 rpm. Then petroleum ether is poured in. The resulting suspension of nanocapsules is filtered and dried at room temperature. The core/shell ratio in nanocapsules is 1:1, or 5:1, or 1:3.EFFECT: method ensures simplification and acceleration of the nanocapsules production process, reduction of losses during the nanocapsules production and can be used in the pharmaceutical and food industries.5 dwg, 10 ex

C6-c18-acylated derivative of hyaluronic acid, method for production nanomicellar composition based thereon, method for production and method for production of stabilized nanomicellar composition and its application // 2640287
FIELD: pharmacology.SUBSTANCE: invention relates to a method for production of hydrophobised hyaluronic acid (Formula I). R is H+ or Na+ and R1 is H or -C(=O)CxHy or -C(═O)CH=CH-het, where x is an integer ranging from 5 to 17, and y is an integer ranging from 11 to 35, and CxHy is a linear or branched, saturated or unsaturated C5-C17 chain and het is a heterocyclic or heteroaromatic group with an arbitrary content of N, S or O atoms with at least one repeating unit containing one or more R1 -C(=O)CxHy or -C(=O)CH=CH-het groups, and where n is ranging from 12 to 4000. A method for production of this hyaluronic acid derivative, a nanomicellar composition based thereon, a method for production of a nanomicellar composition and its application in pharmaceutical and cosmetic applications, as well as a method for production of its stabilized form are also proposed.EFFECT: ensured transfer of bound substances from the hydrophobic domains of nanomicelle to the cell.35 cl, 12 dwg, 1 tbl, 38 ex
Liquid marker for determination of respiratory epithelial clearance speed of nasal mucosa and maxillary sinus // 2640174
FIELD: medicine.SUBSTANCE: liquid marker for determination respiratory epithelial clearance speed of the nasal mucosa and maxillary sinus contains methylene blue, anesthesin, saccharin, sodium laurisulfate and distilled water. The ingredients are used in the declared amounts.EFFECT: application of the invention allows to determine the speed of mucus transport over the surface of the mucosa and gives a characterization of the human respiratory epithelial clearance system as a whole.1 ex

ethod for producing nanocapsules of dry extract of topinambur // 2640130
FIELD: nanotechnology.SUBSTANCE: dry extract of topinambur is added to a suspension containing sodium alginate in butanole and drug E472c as a surface-active substance, then petroleum-ether is added, the obtained suspension of nanocapsules is filtered, washed with petroleum-ether and dried. The ratio core: shell is 1:1, 1:3, 1:5 or 5:1.EFFECT: method ensures simplification and acceleration of the nanocapsules production process, reduction of losses during the nanocapsules production and can be used in the pharmaceutical and food industries.2 dwg, 5 ex

ethod for producing aecol nanocapsules // 2640129
FIELD: nanotechnology.SUBSTANCE: method for producing AECol nanocapsules in a shell of sodium alginate is characterized in that AECol is added to a suspension of sodium alginate in benzene in the presence of 0.01 g of E472c as a surface-active substance, followed by stirring at 1300 rpm. Then 10 ml of diethyl ether is added, after which the resulting suspension is filtered and dried at room temperature, wherein the core/shell weight ratio is 1:1, or 1:3, or 3:1, or 1:5.EFFECT: simplification and acceleration of the nanocapsules production process, reduction of losses during the nanocapsules production and can be used to create biologically active additives and for the food processing industry.1 dwg, 5 ex

ethod for producing aecol nanocapsules // 2640128
FIELD: nanotechnology.SUBSTANCE: method for producing AECol nanocapsules in a shell of sodium carboxymethylcellulose is characterized in that AECol is added to a suspension of sodium carboxymethylcellulose in benzene in the presence of 0.01 g of E472c as a surface-active substance, followed by stirring at 1300 rpm, after which 10 ml of petroleum-ether is added, after which the obtained suspension is filtered and dried at room temperature. The ratio core/shell is 1:1, or 1:3, or 3:1, or 1:5.EFFECT: simplification and acceleration of the nanocapsules production process, reduction of losses during the nanocapsules production.1 dwg, 5 ex

ethod for producing nanocapsules of dry extract of topinambur // 2640127
FIELD: nanotechnology.SUBSTANCE: dry extract of topinambur is added to a suspension containing carrageenan in butanole and drug E472c as a surface-active substance, then toluene is added, the obtained suspension of nanocapsules is filtered, washed with toluene and dried. The ratio core: shell is 1:1, 1:3, 1:5 or 5:1.EFFECT: simplification and acceleration of the nanocapsules production process, reduction of losses during the nanocapsules production.3 dwg, 5 ex

In situ crosslinked polymeric compositions and methods for them // 2640084
FIELD: medicine.SUBSTANCE: invention refers to a gel matrix composition for treatment of bleeding wounds consisting of: a) 0.1-5 wt % of sodium alginate; b) 2-25 wt % of chitosan; c) water - the rest.EFFECT: rapid healing of the tissue on which the proposed composition is applied, which is also easily applied and easily removable from the application site.12 cl, 12 dwg
Dermatological reparative means and its external use for skin care, prevention and treatment of skin lesions of various etiology // 2640026
FIELD: medicine.SUBSTANCE: invention is a dermatological reparative means containing zoosterol, lightly crosslinked acrylic polymers, representing acrylic acid homopolymer esters, cross-stitched by allyl saccharose, allyl pentaerythritol or divinyl glycol, preservatives, caustic soda and distilled water, at that, components are at a specific ratio in wt %.EFFECT: increased effectiveness of action due to high adhesion to the skin surface, increased duration of agent action, shortened duration of the healing process, enhanced regeneration of the affected skin, lack of toxicity, and suppression of external allergic reactions.4 cl, 3 tbl

Simple ethers of cellulose that have increased thermal strength of gel // 2640024
FIELD: chemistry.SUBSTANCE: invention relates to a thermogel forming composition, which is produced by combining nanocrystalline cellulose with cellulose ethers. This mixture can be used as a binder in a variety of different cases, for example, in food and raw ceramics. It can also be used to manufacture capsule shells for pharmaceuticals.EFFECT: inventionprovides increased gel strength at a high temperature.12 cl, 1 tbl, 5 ex, 4 dwg
Liquid composition // 2640023
FIELD: pharmacology.SUBSTANCE: invention is an oral bio-available non-aqueous liquid composition containing at least 7 wt % of propylene glycol in the total composition weight, a cardiotonic means, or angiotensin-converting enzyme inhibitor, or combination of cardiotonic means and angiotensin-converting enzyme inhibitor. Invention discloses a method for obtaining the composition described above, by mixing at least 7 wt % of propylene glycol by the total composition weight with a cardiotonic means, or angiotensin-converting enzyme inhibitor, or a combination of cardiotonic means with angiotensin-converting enzyme inhibitor.EFFECT: treatment of heart disease and hypertension.34 cl, 11 dwg, 17 tbl, 2 ex

Composition inhibiting telomerase // 2639819
FIELD: chemistry.SUBSTANCE: composition includes a block-copolymer of polyoxyethylene and polyoxypropylene, as well as a coordination compound of the imidizole-4-one derivative inhibiting telomerase, of the general formula .Herewith the coordination compound of the imidazol-4-one derivative is contained in an amount of 5 to 60 wt %, the block-copolymer is the rest.EFFECT: invention provides a greater effect of telomerase inhibition by increasing the solubility of coordination compounds of the imidazol-4-one derivatives.9 cl, 3 dwg, 2 tbl, 1 ex
Escherichia coli strain - producer of modular nanoconveyor for delivery of pharmaceutical agents to nuclei of target cells // 2639501
FIELD: biotechnology.SUBSTANCE: invention relates to E. coli RosettaTM strain (pRARE2, pR752), RNCIM B-11308. This strain is a producer of a modular nanoconveyor to increase the specificity and effectiveness of antitumor agents of 6His-HMP-NLS-DTox-(Gly-Ser)5-EGF. The present invention makes it possible to obtain a modular 6His-HMP-NLS-DTox-(Gly-Ser)5-EGF nanoconveyor.EFFECT: increase in the specificity and effectiveness of antitumor agents.2 dwg, 2 ex

Pharmaceutical composition containing biotin and method for its production // 2639488
FIELD: pharmacology.SUBSTANCE: group of inventions refers to pharmaceutical compositions for polyneuropathy prevention and treatment as a solid dosage form with extended release, comprising Biotin - 40-60 wt % as an active agent, as well as Methocel K100 LV - 14-21 wt %, Methocel K4M - 5-10 wt %, microcrystalline cellulose (MCC) - 7-18 wt %, copovidone - 1.5-3 wt %, colloidal silicon dioxide - 0.4-1 wt % and a pharmaceutically acceptable stearic acid salt - 0.6-1 wt %, as well as to a method for its production, according to which Biotin, Methocel K4M, Methocel K100 LV, MCC and copovidone are sieved and mixed until homogeneous, stearic acid salt, colloidal silicon dioxide are mixed, the mixture is compacted by rolling, colloidal silicon dioxide is added and mixed together with pre-compacted grains, followed by addition of stearic acid salt, stirring and formation a solid dosage form.EFFECT: creation of a new medicinal composition with high technological properties, high stability and reproducible kinetics of active agent release.9 cl, 8 ex, 5 tbl, 1 dwg

Pharmaceutical compositions // 2639482
FIELD: pharmacology.SUBSTANCE: invention relates to a pharmaceutical composition comprising alisporivir in an amount of 15 to 20 wt % of the composition, water in an amount of 2 to 15 wt % of the composition, a carrier medium comprising a lipophilic component, a surfactant, a hydrophilic component containing ethanol. The composition preferably comprises polyethylene glycol or propylene glycol as the hydrophilic component, medium chain triglycerides or sorbitan monooleate as the lipophilic component, macrogolglycerin hydroxystearate, caprolocaproyl macrogol-8 glyceride or vitamin E polyethylene glycol succinate as the surfactant. The pharmaceutical composition of the invention is intended for oral administration in the form of a capsule.EFFECT: obtaining of an non-oversaturated composition of alisporivir with a high concentration.10 cl, 4 dwg, 12 tbl, 9 ex
Oral antitumour drugs and method for oncological diseases treatment // 2639479
FIELD: pharmacology.SUBSTANCE: group of inventions is an oral agent for oncological diseases treatment, comprising: a therapeutically effective amount of (S)-3-[(3-amino-1-pyrrolidinyl)carbonyl]-4,11-dihydroxy-2-methylanthra[2,3-b]furan-5,10-dione, represented by the formula: and a liquid pharmaceutically acceptable carrier comprising one or more solvents selected from water, polyethylene glycol, 1,2-polypropylene glycol, ethanol, glycerol. The oral agent may be a solid dispersion. The group of inventions includes a method for treatment of an oncological disease, comprising oral administration of a therapeutically effective amount of the described agent to a patient in need.EFFECT: pharmaceuticals according to the invention provide high solubility of anthrafuran, rapid release of the active ingredient from pills or capsules, are stable during storage.13 cl, 1 dwg, 8 tbl, 7 ex
Oral pharmaceutical composition // 2639473
FIELD: pharmacology.SUBSTANCE: invention represents a medicinal form of a non-coated pill containing α,α,α-trifluorothymidine and hydrochloride 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4(1N,3N)pyrimidinedione as active ingredients and, as such, not containing additives, including salt metals. The invention also includes a method for stabilization of an oral pharmaceutical composition containing the active ingredients described above.EFFECT: increased stability of the medicinal form.11 cl, 18 ex, 5 tbl

Ophthalmic composition // 2639472
FIELD: pharmacology.SUBSTANCE: ophthalmic composition in the form of eye drops contains a polyaphron dispersion and has a viscosity of 1 to 50 Pa⋅S at a shear rate of 1 s-1,wherein the said composition comprises a non-ionic, non-halogenated surfactant, a pharmaceutically acceptable oil selected from the group consisting of castor oil, long chain triglycerides, medium chain triglycerides, mineral oil, silicones, phospholipids, mono- and diglycerides, and mixtures of two or more thereof, and a pharmaceutically active agent - cyclosporin, wherein the composition does not contain a fluorinated surfactant.EFFECT: improved active agent penetration through the cornea.14 cl, 10 ex, 1 dwg
 
2550979.
Up!